Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 2,503 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,503 shares of the firm’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $77,067.37. Following the transaction, the chief operating officer now directly owns 203,783 shares in the company, valued at $6,274,478.57. The trade was a 1.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total value of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.15, for a total value of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $28.18, for a total value of $281,800.00.

Akero Therapeutics Price Performance

Shares of NASDAQ AKRO traded down $1.32 during mid-day trading on Thursday, reaching $29.03. 332,877 shares of the company were exchanged, compared to its average volume of 844,207. The company’s 50 day moving average price is $30.77 and its 200 day moving average price is $26.99. Akero Therapeutics, Inc. has a 52 week low of $15.32 and a 52 week high of $37.00. The company has a quick ratio of 17.25, a current ratio of 17.25 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $2.03 billion, a PE ratio of -7.74 and a beta of -0.23.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings data on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). Sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Akero Therapeutics

Large investors have recently added to or reduced their stakes in the company. Simplify Asset Management Inc. raised its holdings in shares of Akero Therapeutics by 15.6% during the third quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after acquiring an additional 38,279 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after purchasing an additional 112,426 shares during the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Akero Therapeutics by 32.8% during the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock valued at $5,894,000 after acquiring an additional 61,988 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Akero Therapeutics by 26.1% in the second quarter. The Manufacturers Life Insurance Company now owns 107,172 shares of the company’s stock worth $2,514,000 after buying an additional 22,195 shares during the last quarter. Finally, Propel Bio Management LLC boosted its stake in Akero Therapeutics by 4.9% during the 3rd quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock valued at $9,862,000 after purchasing an additional 15,977 shares during the last quarter.

Wall Street Analyst Weigh In

AKRO has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup began coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $65.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Akero Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.